About this trial
The scarcity of evidence regarding the interchangeable use of different progestogens poses challenges, particularly in international egg donation and fertility preservation programs where standardizing protocols is crucial for achieving consistent efficacy, efficiency, and safety outcomes. Consequently, there's a pressing need for clinical studies to assess the effects of various progestogens on clinical outcomes in controlled ovarian hyperstimulation cycles. This study, a pioneering effort, aims to compare the effects of two progestogens on oocyte performance, safety, and efficiency in an egg donation program involving young, healthy, normo-responding patients.
Eligibility criteria
Qualifiers
BMI of 18-29,9 kg/m2
Ultrasound count of antral follicles prior to COH ≥ 12 follicles
Meeting the criteria for inclusion in the egg donation program
Normal karyotype and no active sexually transmitted diseases
Disqualifiers
Patients excluded from the egg donation program
Untreated sexually transmitted diseases, positive serology for HBV, HIV, HCV
Blood disorders, neurodegenerative/psychiatric diseases, carriers of X-linked genetic diseases, oncological diseases, endometriosis.
Oligomenorrhea (<1 menstrual cycle in 3 months)
Trial design
Treatments tested in this trial
- Cerazet
Treatment groups
Sponsors and collaborators
NextFertility
Lead sponsor
SINAE SL
Collaborator